JCS Medical, Change of Major Shareholder

JCS Medical announced on the 10th that its largest shareholder is scheduled to change to Syracuse Subco.

Syracuse Subco is a corporation newly established in Korea by Archimed in April, and it announced that from this day until the 22nd of next month, it will conduct a tender offer to purchase 55,724,838 common shares of JCS Medical at 13,000 KRW per share. This corresponds to 72.0% of the total potential issued shares of JCS Medical.

The total amount is approximately 724.4 billion KRW, and NH Investment & Securities is the lead manager for the tender offer.

Archimed is a France-based private equity fund management company established in 2014, primarily investing in the healthcare sector including bio-pharmaceuticals, medical technology, and in vitro diagnostics.